BKM Wealth Management LLC Purchases 2,963 Shares of Bristol-Myers Squibb (NYSE:BMY)

BKM Wealth Management LLC raised its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 151.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,924 shares of the biopharmaceutical company’s stock after purchasing an additional 2,963 shares during the period. BKM Wealth Management LLC’s holdings in Bristol-Myers Squibb were worth $267,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Northwest Financial Advisors purchased a new stake in Bristol-Myers Squibb during the fourth quarter valued at approximately $27,000. Pacific Capital Wealth Advisors Inc. purchased a new stake in Bristol-Myers Squibb during the fourth quarter valued at approximately $34,000. Turtle Creek Wealth Advisors LLC purchased a new stake in Bristol-Myers Squibb during the fourth quarter valued at approximately $40,000. Wetzel Investment Advisors Inc. purchased a new stake in Bristol-Myers Squibb during the fourth quarter valued at approximately $40,000. Finally, Fairman Group LLC purchased a new stake in Bristol-Myers Squibb during the fourth quarter valued at approximately $42,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Stock Down 0.6 %

Shares of NYSE BMY opened at $41.30 on Tuesday. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99. The stock has a market capitalization of $83.72 billion, a PE ratio of -13.32, a price-to-earnings-growth ratio of 14.21 and a beta of 0.44. The stock’s fifty day simple moving average is $42.97 and its two-hundred day simple moving average is $48.11. Bristol-Myers Squibb has a 12-month low of $39.63 and a 12-month high of $65.38.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.53) by $0.13. The business had revenue of $11.87 billion for the quarter, compared to analysts’ expectations of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The business’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same quarter last year, the firm earned $2.05 EPS. As a group, analysts expect that Bristol-Myers Squibb will post 0.58 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, August 1st. Stockholders of record on Friday, July 5th will be given a $0.60 dividend. The ex-dividend date is Friday, July 5th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 5.81%. Bristol-Myers Squibb’s payout ratio is -77.42%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on BMY shares. Societe Generale downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Barclays reduced their price target on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a report on Friday, April 26th. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. StockNews.com downgraded Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 27th. Finally, BMO Capital Markets reduced their price target on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a report on Friday, April 26th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $60.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.